帕金森患者对风险的耐受性和等待新型神经刺激装置潜在益处的意愿:一项以患者为中心的阈值技术研究。

IF 1.7
MDM policy & practice Pub Date : 2021-01-18 eCollection Date: 2021-01-01 DOI:10.1177/2381468320978407
Brett Hauber, Brennan Mange, Mo Zhou, Shomesh Chaudhuri, Heather L Benz, Brittany Caldwell, John P Ruiz, Anindita Saha, Martin Ho, Stephanie Christopher, Dawn Bardot, Margaret Sheehan, Anne Donnelly, Lauren McLaughlin, Katrina Gwinn, Andrew Lo, Murray Sheldon
{"title":"帕金森患者对风险的耐受性和等待新型神经刺激装置潜在益处的意愿:一项以患者为中心的阈值技术研究。","authors":"Brett Hauber,&nbsp;Brennan Mange,&nbsp;Mo Zhou,&nbsp;Shomesh Chaudhuri,&nbsp;Heather L Benz,&nbsp;Brittany Caldwell,&nbsp;John P Ruiz,&nbsp;Anindita Saha,&nbsp;Martin Ho,&nbsp;Stephanie Christopher,&nbsp;Dawn Bardot,&nbsp;Margaret Sheehan,&nbsp;Anne Donnelly,&nbsp;Lauren McLaughlin,&nbsp;Katrina Gwinn,&nbsp;Andrew Lo,&nbsp;Murray Sheldon","doi":"10.1177/2381468320978407","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background.</b> Parkinson's disease (PD) is neurodegenerative, causing motor, cognitive, psychological, somatic, and autonomic symptoms. Understanding PD patients' preferences for novel neurostimulation devices may help ensure that devices are delivered in a timely manner with the appropriate level of evidence. Our objective was to elicit preferences and willingness-to-wait for novel neurostimulation devices among PD patients to inform a model of optimal trial design. <b>Methods.</b> We developed and administered a survey to PD patients to quantify the maximum levels of risks that patients would accept to achieve potential benefits of a neurostimulation device. Threshold technique was used to quantify patients' risk thresholds for new or worsening depression or anxiety, brain bleed, or death in exchange for improvements in \"on-time,\" motor symptoms, pain, cognition, and pill burden. The survey elicited patients' willingness to wait to receive treatment benefit. Patients were recruited through Fox Insight, an online PD observational study. <b>Results.</b> A total of 2740 patients were included and a majority were White (94.6%) and had a 4-year college degree (69.8%). Risk thresholds increased as benefits increased. Threshold for depression or anxiety was substantially higher than threshold for brain bleed or death. Patient age, ambulation, and prior neurostimulation experience influenced risk tolerance. Patients were willing to wait an average of 4 to 13 years for devices that provide different levels of benefit. <b>Conclusions.</b> PD patients are willing to accept substantial risks to improve symptoms. Preferences are heterogeneous and depend on treatment benefit and patient characteristics. The results of this study may be useful in informing review of device applications and other regulatory decisions and will be input into a model of optimal trial design for neurostimulation devices.</p>","PeriodicalId":520707,"journal":{"name":"MDM policy & practice","volume":" ","pages":"2381468320978407"},"PeriodicalIF":1.7000,"publicationDate":"2021-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2381468320978407","citationCount":"13","resultStr":"{\"title\":\"Parkinson's Patients' Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study.\",\"authors\":\"Brett Hauber,&nbsp;Brennan Mange,&nbsp;Mo Zhou,&nbsp;Shomesh Chaudhuri,&nbsp;Heather L Benz,&nbsp;Brittany Caldwell,&nbsp;John P Ruiz,&nbsp;Anindita Saha,&nbsp;Martin Ho,&nbsp;Stephanie Christopher,&nbsp;Dawn Bardot,&nbsp;Margaret Sheehan,&nbsp;Anne Donnelly,&nbsp;Lauren McLaughlin,&nbsp;Katrina Gwinn,&nbsp;Andrew Lo,&nbsp;Murray Sheldon\",\"doi\":\"10.1177/2381468320978407\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background.</b> Parkinson's disease (PD) is neurodegenerative, causing motor, cognitive, psychological, somatic, and autonomic symptoms. Understanding PD patients' preferences for novel neurostimulation devices may help ensure that devices are delivered in a timely manner with the appropriate level of evidence. Our objective was to elicit preferences and willingness-to-wait for novel neurostimulation devices among PD patients to inform a model of optimal trial design. <b>Methods.</b> We developed and administered a survey to PD patients to quantify the maximum levels of risks that patients would accept to achieve potential benefits of a neurostimulation device. Threshold technique was used to quantify patients' risk thresholds for new or worsening depression or anxiety, brain bleed, or death in exchange for improvements in \\\"on-time,\\\" motor symptoms, pain, cognition, and pill burden. The survey elicited patients' willingness to wait to receive treatment benefit. Patients were recruited through Fox Insight, an online PD observational study. <b>Results.</b> A total of 2740 patients were included and a majority were White (94.6%) and had a 4-year college degree (69.8%). Risk thresholds increased as benefits increased. Threshold for depression or anxiety was substantially higher than threshold for brain bleed or death. Patient age, ambulation, and prior neurostimulation experience influenced risk tolerance. Patients were willing to wait an average of 4 to 13 years for devices that provide different levels of benefit. <b>Conclusions.</b> PD patients are willing to accept substantial risks to improve symptoms. Preferences are heterogeneous and depend on treatment benefit and patient characteristics. The results of this study may be useful in informing review of device applications and other regulatory decisions and will be input into a model of optimal trial design for neurostimulation devices.</p>\",\"PeriodicalId\":520707,\"journal\":{\"name\":\"MDM policy & practice\",\"volume\":\" \",\"pages\":\"2381468320978407\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2021-01-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1177/2381468320978407\",\"citationCount\":\"13\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MDM policy & practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/2381468320978407\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MDM policy & practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2381468320978407","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 13

摘要

背景。帕金森病(PD)是一种神经退行性疾病,引起运动、认知、心理、躯体和自主神经症状。了解PD患者对新型神经刺激装置的偏好可能有助于确保装置在适当的证据水平下及时交付。我们的目标是激发PD患者对新型神经刺激装置的偏好和等待意愿,从而为最佳试验设计模型提供信息。方法。我们对PD患者进行了一项调查,以量化患者为获得神经刺激装置的潜在益处而接受的最大风险水平。阈值技术用于量化患者新发或恶化的抑郁或焦虑、脑出血或死亡的风险阈值,以换取“准时”、运动症状、疼痛、认知和药物负担的改善。通过问卷调查,了解患者等待治疗效果的意愿。患者是通过在线PD观察研究Fox Insight招募的。结果。共纳入2740例患者,大多数为白人(94.6%),具有4年制大学学历(69.8%)。风险阈值随着收益的增加而增加。抑郁或焦虑的阈值明显高于脑出血或死亡的阈值。患者的年龄、活动和先前的神经刺激经历影响风险承受能力。患者愿意平均等待4到13年,以获得不同程度的益处。结论。PD患者愿意接受较大的风险来改善症状。偏好是不同的,取决于治疗效果和患者特征。这项研究的结果可能有助于审查设备应用和其他监管决策,并将被输入到神经刺激设备的最佳试验设计模型中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Parkinson's Patients' Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study.

Parkinson's Patients' Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study.

Parkinson's Patients' Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study.

Parkinson's Patients' Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study.

Background. Parkinson's disease (PD) is neurodegenerative, causing motor, cognitive, psychological, somatic, and autonomic symptoms. Understanding PD patients' preferences for novel neurostimulation devices may help ensure that devices are delivered in a timely manner with the appropriate level of evidence. Our objective was to elicit preferences and willingness-to-wait for novel neurostimulation devices among PD patients to inform a model of optimal trial design. Methods. We developed and administered a survey to PD patients to quantify the maximum levels of risks that patients would accept to achieve potential benefits of a neurostimulation device. Threshold technique was used to quantify patients' risk thresholds for new or worsening depression or anxiety, brain bleed, or death in exchange for improvements in "on-time," motor symptoms, pain, cognition, and pill burden. The survey elicited patients' willingness to wait to receive treatment benefit. Patients were recruited through Fox Insight, an online PD observational study. Results. A total of 2740 patients were included and a majority were White (94.6%) and had a 4-year college degree (69.8%). Risk thresholds increased as benefits increased. Threshold for depression or anxiety was substantially higher than threshold for brain bleed or death. Patient age, ambulation, and prior neurostimulation experience influenced risk tolerance. Patients were willing to wait an average of 4 to 13 years for devices that provide different levels of benefit. Conclusions. PD patients are willing to accept substantial risks to improve symptoms. Preferences are heterogeneous and depend on treatment benefit and patient characteristics. The results of this study may be useful in informing review of device applications and other regulatory decisions and will be input into a model of optimal trial design for neurostimulation devices.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信